RecruitingNCT07423546
Cobenfy and dopamine activity in people with schizophrenia
About this title
Read the official source — NCT07423546Medication studyAges 18–50United States
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 1, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 12
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT07423546
- Official title
Show the full official title
A Multimodal PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Recruitment & locations
RecruitingNew York
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Does this study involve medication?
Yes. The study involves medication, including Xanomeline and trospium chloride (KarXT).
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
